文献速递艾滋病与性传播感染

VH3810109在未接受抗逆转录病毒治疗的HIV-1成人中的疗效、安全性、药代动力学及抗药抗体发生率:BANNER研究结果

VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.
PubMed 文献 · J Infect Dis · 2025-01-01

BANNER是一项随机、开放标签、2部分、多中心2a期研究,评估CD4结合位点抗体VH3810109(N6LS)在未接受抗逆转录病毒治疗(ART)且HIV-1 RNA≥5000拷贝/mL的成人中的疗效与安全性。单次静脉输注或皮下注射单药治疗后,病毒学应答率随剂量不同而异,最高剂量组达100%。N6LS耐受性良好,药代动力学参数随剂量成比例增加,抗药抗体发生率呈剂量依赖性(静脉组6%–83%,皮下组19%)。

要点

  • N6LS单药治疗在较高剂量下显示出良好抗病毒活性,40 mg/kg静脉组病毒学应答率100%。
  • N6LS静脉或皮下给药耐受性良好,单药治疗期间未报告严重不良事件。
  • 抗药抗体发生率呈剂量依赖性,静脉组6%–83%,皮下组19%。

核心结论

  • N6LS在未接受ART的HIV-1成人中具有疗效且总体安全,支持进一步开发静脉或皮下给药的N6LS用于HIV-1治疗。

研究设计与样本

  • BANNER为随机、开放标签、2部分、多中心2a期研究,纳入未接受ART且HIV-1 RNA≥5000拷贝/mL的成人。
  • 单次静脉输注不同剂量或皮下注射N6LS进行单药治疗,随后接受48周标准ART。

主要发现

  • 病毒学应答(HIV-1 RNA较基线下降≥0.5 log10拷贝/mL)率:40 mg/kg静脉组8/8(100%),700 mg静脉组14/15(93%),280 mg静脉组5/6(83%),70 mg静脉组7/16(44%),700 mg皮下组8/16(50%)。
  • 单药治疗期间药物相关不良事件少(n=13),未报告严重不良事件。
  • 药代动力学参数随剂量成比例增加。
  • 抗药抗体发生率呈剂量依赖性,静脉组范围为6%至83%,皮下组为19%,未提示给药途径影响抗药抗体发生率。

临床怎么用

  • N6LS单药治疗在较高剂量下显示良好抗病毒活性,但需进一步研究确定最佳剂量和给药途径。
  • 治疗期间需监测抗药抗体发生,尤其在高剂量静脉给药时发生率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VH3810109 (N6LS) is a CD4-binding site antibody with broad and potent neutralizing activity in vitro. Here, we present efficacy, safety, and pharmacokinetic results from the phase 2a BANNER study in people with HIV-1. METHODS: BANNER was a randomized, open-label, 2-part, multicenter study of N6LS in adults naive to antiretroviral therapy (ART) with HIV-1 RNA ≥5000 copies/mL. N6LS was evaluated during monotherapy after a single intravenous (IV) infusion at various doses or subcutaneous (SC) injection, followed by 48 weeks of standard-of-care ART. Antiviral activity, safety, pharmacokinetics, and antidrug antibodies (ADAs) were evaluated. RESULTS: Sixty-two participants completed the monotherapy phase and 58 completed the standard-of-care phase. Most participants were male (94%), Hispanic (82%), and White (61%). Virologic response (reduction in HIV-1 RNA ≥0.5 log10 copies/mL from baseline) was achieved in 8/8 (100%; 40 mg/kg IV), 14/15 (93%; 700 mg IV), 5/6 (83%; 280 mg IV), 7/16 (44%; 70 mg IV), and 8/16 (50%; 700 mg SC) participants. Administered IV or SC, N6LS was well tolerated with few drug-related adverse events (n = 13) and no serious adverse events reported during monotherapy. Pharmacokinetic parameters increased proportionally with dose. Incidence of ADAs was dose-dependent and ranged from 6% to 83% in the IV groups; incidence was 19% in the SC group, with no indication that route of administration impacts incidence of ADAs. CONCLUSIONS: N6LS was efficacious and generally safe, supporting further development of N6LS dosed IV or SC for the treatment of HIV-1 (ClinicalTrials.gov, NCT04871113).

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Leone PA, Ferro A, Rolle CP, et al. VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results. J Infect Dis. 2025. PMID: 40892985. doi:10.1093/infdis/jiaf450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。